We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
26
DELISTED
Assertio
ASRT
$6.79M 0.87%
6,000
+3,000
+100% +$5.12M
XLY icon
27
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$22.6B
$6.63M 0.85%
+178,432
New +$6.86M
VNDA icon
28
Vanda Pharmaceuticals
VNDA
$307M
$5.79M 0.74%
513,390
– –
CHKP icon
29
Check Point Software Technologies
CHKP
$13B
$5.74M 0.73%
72,327
-18,760
-21% -$1.5M
ALXN
30
DELISTED
Alexion Pharmaceuticals
ALXN
$5.47M 0.7%
+35,000
New +$6.38M
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$4.71M 0.6%
117,500
+30,000
+34% +$1.64M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$4.34M 0.55%
310,000
-140,000
-31% -$2.2M
EGLT
33
DELISTED
Egalet Corporation
EGLT
$4.28M 0.55%
+325,000
New +$4.13M
PTCT icon
34
CALL
PTC Therapeutics
PTCT
$5.68B
$4.27M 0.55%
1,600
+1,000
+167% +$42.8K
ITCI
35
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.22M 0.54%
105,400
-22,600
-18% -$737K
VRTX icon
36
Vertex Pharmaceuticals
VRTX
$121B
$4.17M 0.53%
+40,000
New +$5.14M
ALDR
37
DELISTED
Alder Biopharmaceuticals
ALDR
$4.09M 0.52%
125,000
– –
PTLA
38
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.05M 0.52%
95,000
+9,000
+10% +$434K
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.96M 0.51%
+200,000
New +$6.32M
ZVRA icon
40
Zevra Therapeutics
ZVRA
$562M
$3.96M 0.51%
12,775
-2,069
-14% -$634K
GWPH
41
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.94M 0.5%
43,100
-400
-0.9% -$44.5K
UTHR icon
42
United Therapeutics
UTHR
$25.8B
$3.79M 0.48%
28,840
– –
CNCE
43
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.75M 0.48%
200,000
+184,142
+1,161% +$3.13M
MGNX icon
44
MacroGenics
MGNX
$235M
$3.64M 0.46%
170,000
+85,000
+100% +$2.67M
SBUX icon
45
Starbucks
SBUX
$120B
$3.56M 0.45%
62,683
+9,100
+17% +$510K
RPTP
46
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$3.53M 0.45%
584,089
+377,589
+183% +$4.63M
ARRY
47
CALL
DELISTED
Array Biopharma Inc
ARRY
$3.42M 0.44%
+7,500
New +$44.5K
AMAG
48
DELISTED
AMAG Pharmaceuticals
AMAG
$3.39M 0.43%
85,230
-5,000
-6% -$310K
BLCM
49
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$3.36M 0.43%
23,151
– –
CPRX
50
DELISTED
Catalyst Pharmaceutical
CPRX
$3.3M 0.42%
1,100,000
-100,000
-8% -$432K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.